针对肥胖和脂质新陈代谢的个人资料,以预防近腹:一个病例对照研究和门德尔随机化分析
Huang-Fu Ma1, Jia-Hua Qian2, Yi-Hao Chen3
1Department of Proctology, China-Japan Friendship Hospital, Beijing 100029, China.
World journal of gastrointestinal surgery
|February 16, 2026
概括
肥胖和脂肪代谢的改变显著增加了近腹 (PA) 的风险. 了解这些联系,包括体重指数 (BMI) 和甘油三水平,可以指导新的预防策略.
科学领域:
- 代谢障碍 代谢障碍 代谢障碍
- 手术病理学手术病理学
背景情况:
- 周围 (PAs) 会导致严重的并发症,如抽和复发性感染.
- 目前缺乏有效的PAS初级和二级预防策略.
研究的目的:
- 为了研究肥胖,脂质代谢物和围的出现之间的联系.
主要方法:
- 进行了一项病例控制研究和门德尔随机化 (MR) 分析.
- 数据包括身体尺寸,血清代谢物和与PAS和肥胖相关的遗传变异.
- 评估的结果是PA发作,数量和位置.
主要成果:
- 较高的BMI,腰与部比率 (WHR),腰与身高比率 (WHtR),葡萄糖,尿酸 (UA),总胆固醇,甘油三和LDL与增加的PA风险有关.
- 升高的HDL水平与降低的PA风险相关.
- 肥胖指标和脂质资料也与PA数量和严重程度相关.
结论:
- 肥胖和特定的脂质代谢概况始终与较高的周腹风险有关.
- 这些发现支持开发新型的PAS初级和二级预防策略.
相关概念视频
Lipid Absorption
2.8K
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
2.8K
Pharmacogenomics: Identification of New Drug Targets
9
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
9
Atherosclerosis III: Management
459
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
459
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
301
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
301
Lipid Digestion
100.1K
Lipids are large molecules that are generally not water-soluble. Since most of the digestive enzymes in the human body are water-based, there are specific steps the body must take to break down lipids and make them available for use.
100.1K

